Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine"
DOI: 10.1007/s12020-020-02424-z
Abstract: Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further… read more here.
Keywords: lanreotide autogel; autogel 120; control; extended dosing ... See more keywords
Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-01112-3
Abstract: Although the previous lanreotide autogel/depot syringe had been well received, feedback indicated that improvements could be made to make it more user-friendly. Additionally, the view that patients should have greater involvement in the research and… read more here.
Keywords: lanreotide autogel; depot syringe; syringe; autogel depot ... See more keywords
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.06.056
Abstract: INTRODUCTION This prospective, single-arm, phase 2 study assessed the efficacy and safety of lanreotide autogel (LAN) administered at a reduced dosing interval in patients with progressive neuroendocrine tumours (NETs) after LAN standard regimen. METHODS Patients… read more here.
Keywords: patients progressive; lanreotide autogel; efficacy safety; safety ... See more keywords
Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report
Sign Up to like & getrecommendations! Published in 2017 at "Case Reports in Gastroenterology"
DOI: 10.1159/000485025
Abstract: Gastrinomas are functionally active pancreatic neuroendocrine tumors (NETs) secreting gastrin and are associated with local or regional metastases in 60% of the cases. Somatostatin analogs (SSAs) are currently recommended as a first-line treatment for the… read more here.
Keywords: lanreotide autogel; treatment; case; report ... See more keywords